Oncocyte (IMDX) FDA Approvals $5.14 +0.49 (+10.54%) As of 03:17 PM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share FDA Events Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesSEC FilingsShort InterestTrendsBuy This Stock Oncocyte's Drug in the FDA Approval ProcessThis section highlights FDA-related milestones and regulatory updates for drugs developed by Oncocyte (IMDX). Over the past two years, Oncocyte has reported clinical trial outcomes, regulatory submissions, approvals, and other FDA events for drugs and therapies such as GraftAssureDx. For definitions of regulatory abbreviations such as NDA, BLA, or PDUFA, see the event status legend. GraftAssureDx FDA Regulatory Events GraftAssureDx is a drug developed by Oncocyte for the following indication: test kit clinical trial for its planned in vitro diagnostic (IVD). This drug is under review by the U.S. Food and Drug Administration (FDA). Below is a timeline of key regulatory milestones for this therapy. Provided Update - March 3,2026Provided Update Drug: GraftAssureDxAnnounced Date: March 3, 2026Indication: test kit clinical trial for its planned in vitro diagnostic (IVD)AnnouncementInsight Molecular Diagnostics Inc. announced that in February the company completed several major milestones to support the GraftAssureDx™ test kit clinical trial for its planned in vitro diagnostic (IVD) De Novo submission to the U.S. Food and Drug Administration (FDA) and also received its ISO 13485 certification.AI SummaryIn February, Insight Molecular Diagnostics announced several major milestones to support the GraftAssureDx test kit and its planned in vitro diagnostic (IVD) De Novo submission to the U.S. Food and Drug Administration. The company completed a three-site reproducibility study at Tampa General Hospital, Mayo Clinic, and Baylor Scott & White Health. It also said it collected what it believes are sufficient clinical samples to support the statistical analysis needed for the submission. On Feb. 26, Insight received ISO 13485 certification from TÜV SÜD. That certification confirms a regulator-aligned quality management system, helps enable near-term IVD submissions in the U.K., and paves the way for an EU IVD-R filing. The company says the certification should reduce the risk of surprises during regulatory review and lower quality risk for future manufacturing. Insight is finishing internal analytical performance testing; of roughly 12,000 instrument and assay cycles needed for the FDA package, about 340 remain. The company aims to make GraftAssureDx available for clinical use beginning in 2026 to expand access to transplant organ health testing.Read Announcement Oncocyte FDA Events - Frequently Asked Questions Has Oncocyte received FDA approval? As of now, Oncocyte (IMDX) has not received any FDA approvals for its therapy in the last two years. What drugs has Oncocyte submitted to the FDA? In the past two years, Oncocyte (IMDX) has reported FDA regulatory activity for GraftAssureDx. What is the most recent FDA event for Oncocyte? The most recent FDA-related event for Oncocyte occurred on March 3, 2026, involving GraftAssureDx. The update was categorized as "Provided Update," with the company reporting: "Insight Molecular Diagnostics Inc. announced that in February the company completed several major milestones to support the GraftAssureDx™ test kit clinical trial for its planned in vitro diagnostic (IVD) De Novo submission to the U.S. Food and Drug Administration (FDA) and also received its ISO 13485 certification." What conditions do Oncocyte's current drugs treat? Currently, Oncocyte has one therapy (GraftAssureDx) targeting the following condition: test kit clinical trial for its planned in vitro diagnostic (IVD). More FDA Event Resources from MarketBeat FDA Calendars Recent FDA Drug Approval Calendar Upcoming FDA Events & PDUFA Dates Calendar Companies With Recent FDA Events Acurx Pharmaceuticals FDA EventsAkebia Therapeutics FDA EventsAltimmune FDA EventsEstrella Immunopharma FDA EventsNiagen Bioscience FDA EventsOmeros FDA EventsOSR FDA EventsRocket Pharmaceuticals FDA EventsTonix Pharmaceuticals FDA EventsZai Lab FDA EventsEli Lilly and Company FDA EventsClearPoint Neuro FDA EventsMoleculin Biotech FDA EventsAprea Therapeutics FDA EventsCapricor Therapeutics FDA Events FDA Event Stage Terminology & Abbreviation Guide NDA: New Drug Application ANDA: Abbreviated New Drug Application sNDA: Supplemental New Drug Application BLA: Biologics License Application sBLA: Supplemental Biologics License Application FDA Approved: Approved by the FDA EMA: European Medicines Agency CE Mark: European Union Certification NMPA: China National Medical Products Administration MHLW: Japanese Ministry of Health FDA Meeting: Consultation with FDA Pre-IND: Pre-Investigational New Drug Meeting Breakthrough Therapy: Special FDA designation for promising therapies Fast Track: Accelerated FDA approval pathway Orphan Drug: Designation for rare disease treatments RPD: Rare Pediatric Disease Designation RMAT: Regenerative Medicine Advanced Therapy DSMB Review: Data Safety Monitoring Board Review IDMC Review: Independent Data Monitoring Committee MAA: MHRA Marketing Authorization Application RTF: Refusal to File (Rejected Application) 510(k): FDA Clearance for Medical Devices Rolling Submission: Staggered regulatory review process Related Companies Allogene Therapeutics FDA Events Tectonic Therapeutic FDA Events Shattuck Labs FDA Events CytomX Therapeutics FDA Events Relmada Therapeutics FDA Events Altimmune FDA Events Eikon Therapeutics FDA Events Cybin FDA Events 4D Molecular Therapeutics FDA Events Contineum Therapeutics FDA Events Stock Lists Biotechnology StocksCompare Biotech StocksCompare Healthcare StocksCompare Pharmaceutical StocksHealthcare Stocks FDA progress for NASDAQ:IMDX last updated on 3/4/2026 by MarketBeat.com Staff. We continuously monitor for new FDA events and market data. From Our PartnersALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...Weiss Ratings | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredTrump Takes Emergency Action - Plus Elon Musk's New VentureElon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...Altimetry | SponsoredReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...Base Camp Trading | SponsoredCODE RED: AI Meltdown Imminent?After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...Paradigm Press | SponsoredTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredMy top 3 AI picks for the next decadeAlexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up A...The Oxford Club | SponsoredWhere to Put $100 Before Trump's New Tech Law Rolls OutThe Financial Times says a new tech law puts America 'on the verge of a financial revolution.' Yahoo Finance e...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Oncocyte Corp Please log in to your account or sign up in order to add this asset to your watchlist. Share Oncocyte With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Provided Update - March 3,2026Provided Update Drug: GraftAssureDxAnnounced Date: March 3, 2026Indication: test kit clinical trial for its planned in vitro diagnostic (IVD)AnnouncementInsight Molecular Diagnostics Inc. announced that in February the company completed several major milestones to support the GraftAssureDx™ test kit clinical trial for its planned in vitro diagnostic (IVD) De Novo submission to the U.S. Food and Drug Administration (FDA) and also received its ISO 13485 certification.AI SummaryIn February, Insight Molecular Diagnostics announced several major milestones to support the GraftAssureDx test kit and its planned in vitro diagnostic (IVD) De Novo submission to the U.S. Food and Drug Administration. The company completed a three-site reproducibility study at Tampa General Hospital, Mayo Clinic, and Baylor Scott & White Health. It also said it collected what it believes are sufficient clinical samples to support the statistical analysis needed for the submission. On Feb. 26, Insight received ISO 13485 certification from TÜV SÜD. That certification confirms a regulator-aligned quality management system, helps enable near-term IVD submissions in the U.K., and paves the way for an EU IVD-R filing. The company says the certification should reduce the risk of surprises during regulatory review and lower quality risk for future manufacturing. Insight is finishing internal analytical performance testing; of roughly 12,000 instrument and assay cycles needed for the FDA package, about 340 remain. The company aims to make GraftAssureDx available for clinical use beginning in 2026 to expand access to transplant organ health testing.Read Announcement
